JKJolanta Kaszuba-Zwoińska

Jolanta Kaszuba-Zwoińska

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jolanta Kaszuba-Zwoińska has a total of 9 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Immunomodulatory meaning of diet and COVID-19

    by Dominika Grońska, Monika Kłujsza, Aleksandra Pelczar, Jolanta Kaszuba-Zwoińska

    Introduction and objective: The latest scientific reports showed that there is a relationship between the state of the gastrointestinal tract and the immune system, and the incidence of COVID-19. Diet can exert an immunomodulatory effect and regulate the immune response of an organism. The aim...

  • Open Access

    Experimental model for acute kidney injury caused by uropathogenic Escherichia coli

    by Beata Skowron, Agnieszka Baranowska, Jolanta Kaszuba-Zwoińska, Grażyna Więcek, Anna Malska-Woźniak, Piotr Heczko, Magdalena Strus

    Acute kidney injury (AKI) is the rapid deterioration of renal function, diagnosed on the basis of an increase in serum creatinine and abnormal urinary parameters. AKI is associated with increased risk of mortality or chronic kidney disease (CKD). The aim of the study was to develop an experimental model for AKI resulting from Escherichia coli-induced pyelonephritis. E. coli was isolated from a patient with clinical symptoms of urinary tract infection (UTI). The study included three groups of female Wistar rats (groups 1, 2 and 3), in which pyelonephritis was induced by transurethral inoculation with highly virulent E. coli (105, 107 and 109 cfu/ml, respectively). Urine and blood samples for analysis were obtained prior to the inoculation (day 0), as well as 7, 14 and 21 days thereafter. Aside from a microbiological examination of urine samples, daily urine output, serum creatinine (CreaS), creatinine clearance (CrCl), interleukin 6 (IL-6), fractional excretion of sodium (FENa) and fractional excretion of urea (FEUrea) were determined. A histopathological examination of kidney and urinary bladder specimens was conducted as well. While UTI-related pyelonephritis developed irrespective of E. coli inoculum size, AKI was observed only following transurethral administration of E. coli at the intermediate and high dose, i.e. 107 and 109 cfu/ml, respectively (group 2 and 3). An increase in CreaS and abnormal diuresis were accompanied by changes in parameters specific for various forms of AKI, i.e. FENa and FEUrea. Based on these changes, administration of E. coli at 107 cfu/ml was demonstrated to induce renal AKI, whereas inoculation with 109 cfu/ml seemed to cause not only ascending pyelonephritis, but perhaps also bacteremia and urosepsis (prerenal component of AKI).